Pear Therapeutics Overview
Latest ROE for Pear Therapeutics: 81.01% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow81.01%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, PEAR shows a ROE of 81.01%. That is above the sector sector average of -5.72%. Scroll down for historical charts and peer comparison views.
The its sector sector average ROE is about -5.72%. Pear Therapeutics is at 81.01%, which is higher that average. That is roughly 1515.7% above the sector mean. Use the comparison chart on this page to see how PEAR stacks up against individual peers as well.
Check the historical chart to see whether PEAR's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Pear Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Pear Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 81.01%) with ownership activity and broader fundamentals.
